Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.40
+0.06004.48%
Post-market: 1.440.0400+2.86%17:40 EDT
Volume:903.84K
Turnover:1.26M
Market Cap:84.94M
PE:-2.30
High:1.42
Open:1.35
Low:1.34
Close:1.34
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.61M
Volume Ratio:1.27
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:4.11
PE(LYR):-2.00

Loading ...

Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion

Reuters
·
Yesterday

Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

THOMSON REUTERS
·
Yesterday

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

GlobeNewswire
·
Yesterday

Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy

Reuters
·
Sep 15

Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

THOMSON REUTERS
·
Sep 15

Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026

THOMSON REUTERS
·
Sep 15

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

GlobeNewswire
·
Sep 15

MAIA Biotechnology Director Makes Bold Insider Move With Fresh Stock Purchase

TIPRANKS
·
Sep 15

Maia Biotechnology Director Ramiro Guerrero Acquires 37,595 Common Shares Worth $49,511.38

Reuters
·
Sep 14

MAIA Biotechnology Presents Next-Generation Telomere-Targeting Cancer Drug Candidates at IRT 2026

Reuters
·
Sep 10

Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90

Reuters
·
Sep 02

Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02

Reuters
·
Aug 26

Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63

Reuters
·
Aug 25

MAIA Biotechnology files $150M mixed securities shelf

TIPRANKS
·
Aug 22

MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate

Benzinga Earnings
·
Aug 10

Maia Biotech Q2 FY26 Net Loss Widens 49% to $7.94 Million

Reuters
·
Aug 10

Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)

TIPRANKS
·
Jul 10

Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr in 3l Nsclc

Reuters
·
Jul 08

MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion

TIPRANKS
·
Jul 08

Maia Biotech Reports 90.5% Disease Control Rate in Phase 2 Third-line NSCLC Trial Expansion

Reuters
·
Jul 08